Cabaletta Bio, Inc. (CABA) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 10 Buy, 2 Hold.
The consensus price target is $16.33 (low: $3.00, high: $32.00), representing an upside of 400.9% from the current price $3.26.
Analysts estimate Earnings Per Share (EPS) of $-2.34 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.37 vs est $-2.34 (missed -1.3%). 2025: actual $-1.64 vs est $-2.19 (beat +25.1%). Analyst accuracy: 83%.
CABA Stock — 12-Month Price Forecast
$16.33
▲ +400.92% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Cabaletta Bio, Inc., the average price target is $16.33, with a high forecast of $32.00, and a low forecast of $3.00.
The average price target represents a +400.92% change from the last price of $3.26.
Highest Price Target
$32.00
Average Price Target
$16.33
Lowest Price Target
$3.00
CABA Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to Cabaletta Bio, Inc. in the past 3 months
EPS Estimates — CABA
83%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.37
vs Est –$2.34
▼ 1.3% off
2025
Actual –$1.64
vs Est –$2.19
▲ 33.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CABA
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
